Initial monotherapy with eslicarbazepine acetate for the management of adult patients with focal epilepsy in clinical practice: a meta-analysis of observational studies

References

• St Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7(2):77–82.
   PubMed Web of Science ®Google Scholar
• Boon P, Ferrao Santos S, Jansen AC, et al. Recommendations for the treatment of epilepsy in adult and pediatric patients in Belgium: 2020 update. Acta Neurol Belg. 2021;121(1):241–257.
   PubMed Web of Science ®Google Scholar
• Haag A, Strzelczyk A, Bauer S, et al. Quality of life and employment status are correlated with antiepileptic monotherapy versus polytherapy and not with use of "newer" versus "classic" drugs: results of the "Compliant 2006" survey in 907 patients. Epilepsy Behav. 2010;19(4):618–622.
   PubMed Web of Science ®Google Scholar
• Soares-da-Silva P, Pires N, Bonifácio MJ, et al. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action. Pharmacol Res Perspect. 2015;3(2):e00124.
   PubMed Web of Science ®Google Scholar
• Trinka E, Ben-Menachem E, Kowacs PA, et al. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: a phase III double-blind, randomized, parallel-group, multicenter study. Epilepsia. 2018;59(2):479–491.
   PubMed Web of Science ®Google Scholar
• Trinka E, Rocamora R, Chaves J, et al. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: an open-label extension study. Epilepsia. 2020;51(10):1963–1969.
   Google Scholar
• Lattanzi S, Zaccara G, Giovannelli F, et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand. 2019;139(1):33–41.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Belcastro V. What place do carbamazepine-related antiepileptic drugs have in the modern day treatment of epilepsy? Expert Opin Pharmacother. 2020;21(14):1655–1658.
   PubMed Web of Science ®Google Scholar
• Lawthom C, Peltola J, McMurray R, et al. Dibenzazepine agents in epilepsy: how does eslicarbazepine acetate differ? Neurol Ther. 2018;7(2):195–206.
   PubMed Web of Science ®Google Scholar
• O’ Rourke G, O’ Brien JJ. Identifying the barriers to antiepileptic drug adherence among adults with epilepsy. Seizure. 2017;45:160–168.
   PubMed Web of Science ®Google Scholar
• Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110(3):551–555.
   PubMed Web of Science ®Google Scholar
• Perucca E. From clinical trials of antiepileptic drugs to treatment. Epilepsia Open. 2018;3(Suppl 2):220–230.
   PubMedGoogle Scholar
• Sanson-Fisher RW, Bonevski B, Green LW, et al. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med. 2007;33(2):155–161.
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, Ben-Menachem E, Cramer J, et al. The evolution of antiepileptic drug development and regulation. Epileptic Disord. 2010;12(1):3–15.
   PubMed Web of Science ®Google Scholar
• Mohanraj R, Brodie MJ. Measuring the efficacy of antiepileptic drugs. Seizure. 2003;12(7):413–443.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E, Sander JW, Privitera M, et al. Measuring outcomes of treatment with antiepileptic drugs in clinical trials. Epilepsy Behav. 2010;18(1–2):24–30.
   PubMed Web of Science ®Google Scholar
• Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62(12):1305–1312.
   PubMed Web of Science ®Google Scholar
• Garrison LP, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–335.
   PubMed Web of Science ®Google Scholar
• Kälviäinen R. Monotherapy trial design: conversion versus de novo. Epilepsy Res. 2001;45(1–3):75–78.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment of epileptic disorders. London: Science Medicines Health; 2010.
   Google Scholar
• Mattson RH. Monotherapy trials: endpoints. Epilepsy Res. 2001;45(1–3):109–117.
   PubMed Web of Science ®Google Scholar
• Weissinger F, Losch F, Winter Y, et al. Effectiveness of eslicarbazepine acetate in dependency of baseline anticonvulsant therapy: results from a German prospective multicenter clinical practice study. Epilepsy Behav. 2019;101 (Pt A):106574.
   Google Scholar
• Toledano R, Jovel CE, Jiménez-Huete A, et al. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: experience from a multicenter, observational study. Epilepsy Behav. 2017;73:173–179.
   PubMed Web of Science ®Google Scholar
• Giráldez BG, Garamendi-Ruiz I, Zurita J, et al. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: a multicenter audit. Acta Neurol Scand. 2019;140(6):422–428.
   PubMed Web of Science ®Google Scholar
• Holtkamp M, Delanty N, Sales F, et al. Eslicarbazepine acetate as monotherapy in clinical practice: outcomes from Euro-Esli. Acta Neurol Scand. 2019;139(1):49–63.
   PubMed Web of Science ®Google Scholar
• Villanueva V, Bermejo P, Montoya J, et al. MONOZEB: long-term observational study of eslicarbazepine acetate monotherapy. Epilepsy Behav. 2019;97:51–59.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   PubMed Web of Science ®Google Scholar
• Perucca E, Brodie MJ, Kwan P, et al. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544–556.
   PubMed Web of Science ®Google Scholar
• van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58(4):573–578.
   PubMed Web of Science ®Google Scholar
• Watanabe T, Narukawa M. Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan. SpringerPlus. 2016;5(1):905.
   PubMedGoogle Scholar
• Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, et al. A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. Health Qual Life Outcomes. 2011;9(1):83.
   PubMedGoogle Scholar
• Hu Y, Huang Y, Quan F, et al. Comparison of the retention rates between carbamazepine and valproate as an initial monotherapy in Chinese patients with partial seizures: a ten-year follow-up, observational study. Seizure. 2011;20(3):208–213.
   PubMed Web of Science ®Google Scholar
• Lu X, Wang X. Hyponatremia induced by antiepileptic drugs in patients with epilepsy. Expert Opin Drug Saf. 2017;16(1):77–87.
   PubMed Web of Science ®Google Scholar
• Ley M, Principe A, Rocamora R. [Long-term effects of dibenzazepines on metabolic parameters: retrospective comparison of carbamazepine, oxcarbazepine and eslicarbazepine acetate in the real world]. Rev Neurol. 2020;71(2):54–60.
   PubMed Web of Science ®Google Scholar
• Rogin J, Resnick T, Strom L, et al. Analysis of cutaneous allergic reactions in clinical trials of eslicarbazepine acetate. Acta Neurol Scand. 2020;141(5):397–404.
   PubMed Web of Science ®Google Scholar
• Zhu LN, Chen D, Tan G, et al. The tolerability and safety profile of eslicarbazepine acetate in neurological disorders. J Neurol Sci. 2020;413:116772.
   PubMed Web of Science ®Google Scholar